* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS 4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS 5	FEB 05	German (DE) application and patent publication number format changes
NEWS 6	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS 7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS 8	MAR 03	FRANCEPAT now available on STN
NEWS 9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS 10	MAR 29	WPIFV now available on STN
NEWS 11	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS 12	APR 26	PROMT: New display field available
NEWS 13	APR 26	IFIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS 14	APR 26	LITALERT now available on STN
NEWS 15	APR 27	NLDB: New search and display fields available
NEWS 16	May 10	PROUSDDR now available on STN
NEWS 17	May 19	PROUSDDR: One FREE connect hour, per account, in both May and June 2004
NEWS 18	May 12	EXTEND option available in structure searching
NEWS 19	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS 20	May 17	FRFULL now available on STN
NEWS 21	May 27	STN User Update to be held June 7 and June 8 at the SLA 2004 Conference
NEWS 22	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAplus
NEWS 23	May 27	CAplus super roles and document types searchable in REGISTRY
NEWS 24	May 27	Explore APOLLIT with free connect time in June 2004

NEWS EXPRESS	MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 23:03:30 ON 09 JUN 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 23:03:36 ON 09 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 8 JUN 2004 HIGHEST RN 690955-30-7
DICTIONARY FILE UPDATES: 8 JUN 2004 HIGHEST RN 690955-30-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> **file bradykinin () ?agonist?**
'BRADYKININ' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available. If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):**end**

=> **file hcaplus**

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.63

FILE 'HCAPLUS' ENTERED AT 23:04:24 ON 09 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 9 Jun 2004 VOL 140 ISS 24
FILE LAST UPDATED: 8 Jun 2004 (20040608/ED)

This file contains CAS Registry Numbers for easy and accurate
substance identification.

```
=> s bradykinin () ?agonist?
         16404 BRADYKININ
           191 BRADYKININS
         16431 BRADYKININ
                 (BRADYKININ OR BRADYKININS)
        281357 ?AGONIST?
L1         671 BRADYKININ (W) ?AGONIST?

=> s l1 and vascu?
        135827 VASCU?
L2          58 L1 AND VASCU?

=> s l2 and diabet?
        101185 DIABET?
L3           1 L2 AND DIABET?

=> s l3 and review/dt
       1732992 REVIEW/DT
L4           0 L3 AND REVIEW/DT

=> s l2 and review/dt
       1732992 REVIEW/DT
L5           4 L2 AND REVIEW/DT

=> d l5, ibib abs, 1-4

L5   ANSWER 1 OF 4  HCAPLUS  COPYRIGHT 2004 ACS on STN
```

Full Text | Citing References

ACCESSION NUMBER: 2002:895266 HCAPLUS
DOCUMENT NUMBER: 138:395181
TITLE: **Bradykinin antagonists** as new drugs for prostate cancer
AUTHOR(S): Stewart, John M.; Chan, Daniel C.; Simkeviciene, Vitalija; Bunn, Paul A.; Helfrich, Barbara; York, Eunice J.; Taraseviciene-Stewart, Laimute; Bironaite, Daiva; Gera, Lajos
CORPORATE SOURCE: Department of Biochemistry, University of Colorado School of Medicine, Denver, CO, 80262, USA
SOURCE: International Immunopharmacology (2002), 2(13-14), 1781-1786
CODEN: IINMBA; ISSN: 1567-5769
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal; **General Review**
LANGUAGE: English

AB A review. Bradykinin (BK) is an autocrine growth factor for lung and prostate cancers. BK also facilitates tumor extension by increasing tissue permeability and stimulating angiogenesis. Peptide BK antagonists are in development as potential new drugs for lung cancer. Newer nonpeptide BK antagonists have even higher potency against lung cancer, in vitro and in vivo. These compds. have now been applied to the study of prostate cancers, and have been effective. Prostate cancer cell line PC3 is derived from a late-stage, hormone-independent, metastatic tumor; its growth is difficult to inhibit. Our established BK antagonists, while less effective against this line of prostate cancer in xenografts in nude mice than against lung cancer, are active and have led the way to development of new peptide and nonpeptide agents for prostate cancer. In addn. to inhibiting cancer cell growth directly, they inhibit angiogenesis mediated by **vascular** endothelial growth factor, and inhibit increased tissue permeability mediated by membrane metalloproteases in these tumors.

This class of compds. offers hope for development of new drugs for refractory prostate cancer.
REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN
Full Text | Citing References

ACCESSION NUMBER: 2000:324230 HCAPLUS
DOCUMENT NUMBER: 133:83738
TITLE: Kallikrein-kinin system in acute pancreatitis: potential of B2-**bradykinin antagonists** and kallikrein inhibitors
AUTHOR(S): Griesbacher, Thomas
CORPORATE SOURCE: Department of Experimental and Clinical Pharmacology, University of Graz, Graz, A-8010, Austria
SOURCE: Pharmacology (2000), 60(3), 113-120
CODEN: PHMGBN; ISSN: 0031-7012
PUBLISHER: S. Karger AG
DOCUMENT TYPE: Journal; **General Review**
LANGUAGE: English
AB A review with 36 refs. The development of selective antagonists for bradykinin B2 receptors has greatly advanced research on the role of the kallikrein-kinin system in acute pancreatitis. Kinins released during the course of the inflammatory injury are the major cause of the **vascular** symptoms, i.e. pancreatic edema formation and its consequences, such as hemoconcn., hypovolemia and hypotension. Kinins are also involved in the accumulation of potentially cytotoxic factors in the pancreatic tissue. However, treatment with B2 antagonists must begin prior to the formation of pancreatic edema to inhibit or attenuate the **vascular** effects. Visceral pain as a possible target symptom for treatment with B2 antagonists at later time points is suggested by the B2 receptor-mediated activation of nociceptive afferents.
REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN
Full Text | Citing References

ACCESSION NUMBER: 1993:401036 HCAPLUS
DOCUMENT NUMBER: 119:1036
TITLE: Therapeutic prospects of bradykinin receptor antagonists
AUTHOR(S): Sharma, J. N.
CORPORATE SOURCE: Sch. Med. Sci., Univ. Sains Malaysia, Kubang Kerian, 16150, Malay.
SOURCE: General Pharmacology (1993), 24(2), 267-74
CODEN: GEPHDP; ISSN: 0306-3623
DOCUMENT TYPE: Journal; **General Review**
LANGUAGE: English
AB A review with 77 refs. Bradykinin (BK) and related kinins may act on 4 types of receptors designated as B1, B2, B3, and B4. It seems that the B2 receptors are most commonly found in various **vascular** and non-**vascular** smooth muscles, whereas B1 receptors are formed in vitro during trauma, and injury, and are found in bone tissues. These BK receptors are involved in the regulations of various physiol. and pathol. processes. The mode of kinin actions are based upon the interactions between the kinin and their specific receptors, which can led to activation of several second-messenger systems. Numerous BK receptor antagonists have been synthesized with prime aim to treat diseases caused by excessive kinin

prodn. These diseases are RA, inflammatory diseases of the bowel, asthma, rhinitis and sore throat, allergic reactions, pain, inflammatory skin disorders, endotoxin and anaphylactic shock and coronary heart diseases. On the other hand, BK receptor antagonists could be contraindicated in hypertension, since these drugs may antagonize the antihypertensive therapy and/or may trigger the hypertensive crisis. It is worth suggesting that the BK receptor agonists might be useful antihypertensive drugs.

L5 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1968:28157 HCAPLUS
DOCUMENT NUMBER: 68:28157
TITLE: **Bradykinin antagonists** and mediation of **vascular** phenomena of acute inflammation
AUTHOR(S): Rocha e Silva, Mauricio
CORPORATE SOURCE: Dep. Pharmacol., Fac. Med., Univ. Sao Paulo, Sao Paulo, Brazil
SOURCE: Actualites de Physiologie Pathologique (1966), 1, 23-45
CODEN: APPABD; ISSN: 0567-8714
DOCUMENT TYPE: Journal
LANGUAGE: French
AB A discussion and review with 88 references.

=> d his

(FILE 'HOME' ENTERED AT 23:03:30 ON 09 JUN 2004)

FILE 'REGISTRY' ENTERED AT 23:03:36 ON 09 JUN 2004

FILE 'HCAPLUS' ENTERED AT 23:04:24 ON 09 JUN 2004
L1 671 S BRADYKININ () ?AGONIST?
L2 58 S L1 AND VASCU?
L3 1 S L2 AND DIABET?
L4 0 S L3 AND REVIEW/DT
L5 4 S L2 AND REVIEW/DT

=> s l1 and diab?
112055 DIAB?
L6 9 L1 AND DIAB?

=> s l6 and review/dt
1732992 REVIEW/DT
L7 1 L6 AND REVIEW/DT

=> d l7, ibib abs, 1

L7 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2000:263168 HCAPLUS
DOCUMENT NUMBER: 132:317521
TITLE: Organic chemistry 1999. Medicinal chemistry
AUTHOR(S): Garcia-Echeverria, Carlos; Maibaum, Jurgen; Metternich, Rainer; Pombo-Villar, Esteban; Sedrani, Richard; Veenstra, Siem
CORPORATE SOURCE: Novartis Pharma AG, Basel, Switz.

SOURCE: Nachrichten aus der Chemie (2000), 48(3), 284-290
CODEN: NACHFB; ISSN: 1439-9598
PUBLISHER: Wiley-VCH Verlag GmbH
DOCUMENT TYPE: Journal; **General Review**
LANGUAGE: German
AB A review with 80 refs. is given on the following fields of research in medicinal chem. in 1999: protein kinase inhibitors, immunosuppressive substances in transplantation, adiposity and **diabetes**, non-substrate binding sites of proteases, **bradykinin antagonists**, neurokinins, and corticotropin-releasing factor (CRF) antagonists.
REFERENCE COUNT: 111 THERE ARE 111 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 23:03:30 ON 09 JUN 2004)

FILE 'REGISTRY' ENTERED AT 23:03:36 ON 09 JUN 2004

FILE 'HCAPLUS' ENTERED AT 23:04:24 ON 09 JUN 2004
L1 671 S BRADYKININ () ?AGONIST?
L2 58 S L1 AND VASCU?
L3 1 S L2 AND DIABET?
L4 0 S L3 AND REVIEW/DT
L5 4 S L2 AND REVIEW/DT
L6 9 S L1 AND DIAB?
L7 1 S L6 AND REVIEW/DT

=> s l1 and psori?
10739 PSORI?
L8 4 L1 AND PSORI?

=> s l8 and review/dt
1732992 REVIEW/DT
L9 0 L8 AND REVIEW/DT

=> s bradykinin () ?inhib?
16404 BRADYKININ
191 BRADYKININS
16431 BRADYKININ
(BRADYKININ OR BRADYKININS)
1666481 ?INHIB?
L10 319 BRADYKININ (W) ?INHIB?

=> s l10 and review/dt
1732992 REVIEW/DT
L11 12 L10 AND REVIEW/DT

=> d l11, ibib abs, 1-12

L11 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2003:836065 HCAPLUS
DOCUMENT NUMBER: 140:245723
TITLE: Bradykinin-1 receptor antagonists
AUTHOR(S): Bock, Mark G.; Hess, J. Fred; Pettibone, Douglas J.
CORPORATE SOURCE: Merck Research Laboratories, West Point, PA, 19486,

USA
SOURCE: Annual Reports in Medicinal Chemistry (2003), 38, 111-120
CODEN: ARMCBI; ISSN: 0065-7743
PUBLISHER: Elsevier Science
DOCUMENT TYPE: Journal; **General Review**
LANGUAGE: English
AB A review on recent developments in understanding of an active bradykinin B1 receptor mechanism in the central nervous system which has broadened the analgesic potential of blocking this receptor. B1 antagonists exhibit an analgesic profile that overlaps significantly with the opiates, but are unlikely to exhibit the unwanted side effects of morphine-like drugs. Targeting both peripheral and central sites of action could be important for optimizing the efficacy of this novel class of compds.
REFERENCE COUNT: 86 THERE ARE 86 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN
Full Text | Citing References
ACCESSION NUMBER: 2001:824360 HCAPLUS
DOCUMENT NUMBER: 136:177309
TITLE: Inhibition of the renin-angiotensin system, with particular reference to dual blockade treatment
AUTHOR(S): Andersen, Niels Holmark; Mogensen, Carl Erik
CORPORATE SOURCE: Department of Internal Medicine, M Kommunehospitalet University Hospital, DK-Aarhus C, DK-8000, Den.
SOURCE: JRAAS (2001), 2(3), 146-152
CODEN: JRAAAG; ISSN: 1470-3203
PUBLISHER: JRAAS Ltd.
DOCUMENT TYPE: Journal; **General Review**
LANGUAGE: English
AB A review summarizes the latest trials concerning attenuation of the renin-angiotensin system (RAS), highlighting the use of dual blockade treatment. Modulation of RAS has become essential in treating hypertension and delaying the onset of diabetic nephropathy. The use of angiotensin-converting enzyme inhibitors (ACE-I) has beneficial effects when treating hypertension and renal disease in diabetes, as well as non-diabetic renal disease. By dual blockade treatment (combining an ACE-I and an angiotensin AT1-receptor blocker), it might be possible to obtain a more complete inhibition of the RAS and thus greatly enhance the desired therapeutic effect. Dual blockade might also be able to block the effects of both non-ACE pathways and tissue-ACE activity, since both ACE and the AT1-receptor are inhibited simultaneously, thereby increasing bradykinin levels.
REFERENCE COUNT: 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN
Full Text | Citing References
ACCESSION NUMBER: 2000:324230 HCAPLUS
DOCUMENT NUMBER: 133:83738
TITLE: Kallikrein-kinin system in acute pancreatitis: potential of B2-bradykinin antagonists and kallikrein inhibitors
AUTHOR(S): Griesbacher, Thomas
CORPORATE SOURCE: Department of Experimental and Clinical Pharmacology, University of Graz, Graz, A-8010, Austria
SOURCE: Pharmacology (2000), 60(3), 113-120

CODEN: PHMGBN; ISSN: 0031-7012
PUBLISHER: S. Karger AG
DOCUMENT TYPE: Journal; **General Review**
LANGUAGE: English
AB A review with 36 refs. The development of selective antagonists for bradykinin B2 receptors has greatly advanced research on the role of the kallikrein-kinin system in acute pancreatitis. Kinins released during the course of the inflammatory injury are the major cause of the vascular symptoms, i.e. pancreatic edema formation and its consequences, such as hemoconcn., hypovolemia and hypotension. Kinins are also involved in the accumulation of potentially cytotoxic factors in the pancreatic tissue. However, treatment with B2 antagonists must begin prior to the formation of pancreatic edema to inhibit or attenuate the vascular effects. Visceral pain as a possible target symptom for treatment with B2 antagonists at later time points is suggested by the B2 receptor-mediated activation of nociceptive afferents.
REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN
Full Text | Citing References
ACCESSION NUMBER: 2000:264440 HCAPLUS
DOCUMENT NUMBER: 133:26382
TITLE: A novel class of highly potent and orally active nonpeptide bradykinin B2 receptor antagonists
AUTHOR(S): Sawada, Yuki; Kayakiri, Hiroshi; Abe, Yoshito; Satoh, Shigeki; Inoue, Takayuki; Oku, Teruo; Tanaka, Hirokazu
CORPORATE SOURCE: Medicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Ibaraki, 300-2698, Japan
SOURCE: Peptide Science (1999), 36th, 41-44
CODEN: PSCIFQ; ISSN: 1344-7661
PUBLISHER: Japanese Peptide Society
DOCUMENT TYPE: Journal; **General Review**
LANGUAGE: English
AB A review, with 5 refs. describing the authors' work. Highly potent, selective and orally active non-peptide bradykinin B2 receptor antagonists have been discovered. A lead compd. was found by a two-step directed random screening process. Extensive chem. modification of the lead compd. revealed the structure-activity relationships (SAR) and led to discovery of a clin. candidate, FK3657. The active conformation suggested by a mol. modeling study was chem. proved. Further optimization afforded pyrrole derivs. which bind to recombinant human B2 receptors more potently than a second generation peptide B2 antagonist, Icatibant.
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN
Full Text | Citing References
ACCESSION NUMBER: 1997:83423 HCAPLUS
DOCUMENT NUMBER: 126:126991
TITLE: Angiotensin II receptors and renal hemodynamics and function
AUTHOR(S): Ichikawa, Iekuni
CORPORATE SOURCE: Division of Pediatric Nephrology, Vanderbilt University School of Medicine, Nashville, TN, USA
SOURCE: Blood Pressure, Supplement (1996), (2, Angiotensin II Receptors), 19-21
CODEN: BPSUEY; ISSN: 0803-8023

PUBLISHER: Scandinavian University Press
DOCUMENT TYPE: Journal; **General Review**
LANGUAGE: English
AB A review, with 7 refs. The biol. action of angiotensin-converting enzyme (ACE) includes conversion of angiotensin I to angiotensin II (A II) and degrdn. of bradykinin. Thus, pharmacol. blockade of ACE is expected to augment endogenous bradykinin activity. A study using a specific **bradykinin inhibitor** revealed that the activation of bradykinin by an ACE inhibitor has the potential to affect the function of the kidney in several ways. It has been shown in vitro that bradykinin is a highly selective efferent (vs. afferent) arteriolar dilator. An in vivo study using both ACE inhibitors and bradykinin antagonists demonstrated that, through this efferent-arteriolar dilating effect, the bradykinin activated by ACE inhibition causes a profound redn. in glomerular pressure. In contrast, the latter phenomenon is absent during administration of an angiotensin II type 1 (AT1)-receptor antagonist, a finding consistent with the notion that AT1 antagonists are devoid of kininase inhibitory action. Due to this difference, AT1 antagonists appear to be inherently better A II inhibitors than ACE inhibitors where glomerular filtration is concerned. This speculation was verified in an acute exptl. setting. It is conceivable, however, that the relatively high glomerular pressure maintained during AT1-antagonist administration may have different effects on the kidney in the long term, because the salutary effect of ACE inhibition to protect kidneys from progressive damage in chronic renal disease is attributed in part to its potent glomerular-pressure-lowering effect. The long-term effects of losartan in the kidney will need to be examd. in human studies.
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 6 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN
Full Text | Citing References
ACCESSION NUMBER: 1995:198456 HCAPLUS
DOCUMENT NUMBER: 122:1116
TITLE: Bradykinin agonists and antagonists with replacement of proline in position 7 by nonproteinogenic D-amino acids
AUTHOR(S): Reissmann, S.; Greiner, G.; Schwuchow, C.; Pineda, L.F.; Liebmann, C.; Paegelow, I.; Wiesmuller, K.-H.; Stewart, J. M.
CORPORATE SOURCE: Institute of Biochemistry and Biophysics, Friedrich-Schiller-University, Jena, O-6900, Germany
SOURCE: Chemistry of Peptides and Proteins (1993), 5/6(Pt. A), 377-88
CODEN: CHPPER; ISSN: 0723-6271
PUBLISHER: Verlag Mainz, Wissenschaftsverlag
DOCUMENT TYPE: Journal; **General Review**
LANGUAGE: English
AB A review, with 10 refs., on the effects of substitutions in positions seven (and eight) of bradykinin by phenylalanine analogs, Cα-substituted amino acids, and Cβ-substituted amino acids on their agonist and antagonist properties in different biol. systems.

L11 ANSWER 7 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN
Full Text | Citing References
ACCESSION NUMBER: 1994:692888 HCAPLUS
DOCUMENT NUMBER: 121:292888
TITLE: new and highly potent bradykinin antagonists

AUTHOR(S): Knolle, J.; Breipohl, G.; Henke, S.; Wirth, K.; Schoelkens, B.
CORPORATE SOURCE: HOECHST AG, Frankfurt/Main, D-6230, Germany
SOURCE: Chemistry of Peptides and Proteins (1993), 5/6(Pt. A), 389-95
CODEN: CHPPER; ISSN: 0723-6271
PUBLISHER: Verlag Mainz, Wissenschaftsverlag
DOCUMENT TYPE: Journal; **General Review**
LANGUAGE: English
AB A review, with 13 refs., on bradykinin-antagonizing and bradykinin receptor-binding activities achieved by substitutions on bradykinin using isolated guinea pig pulmonary arteries contracted with bradykinin (IC50) and guinea pig ileum with radiolabeled bradykinin (Ki). HOE 140 was chosen for more intensive investigation.

L11 ANSWER 8 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN
Full Text | Citing References
ACCESSION NUMBER: 1990:526633 HCAPLUS
DOCUMENT NUMBER: 113:126633
TITLE: Development of competitive antagonists of bradykinin
AUTHOR(S): Stewart, John M.; Vavrek, Raymond J.
CORPORATE SOURCE: Sch. Med., Univ. Colorado, Denver, CO, 80262, USA
SOURCE: Advances in Experimental Medicine and Biology (1989), 247A(Kinins 5, Pt. A), 81-6
CODEN: AEMBAP; ISSN: 0065-2598
DOCUMENT TYPE: Journal; **General Review**
LANGUAGE: English
AB A review, with 13 refs., on the discovery, characterization, and application of synthetic peptides that are specific and competitive antagonists of bradykinin.

L11 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN
Full Text | Citing References
ACCESSION NUMBER: 1990:471377 HCAPLUS
DOCUMENT NUMBER: 113:71377
TITLE: Kinin antagonists: design and activities
AUTHOR(S): Stewart, John M.; Vavrek, Raymond J.
CORPORATE SOURCE: Sch. Med., Univ. Colorado, Denver, CO, 80262, USA
SOURCE: Journal of Cardiovascular Pharmacology (1990), 15(Suppl. 6), S69-S74
CODEN: JCPCDT; ISSN: 0160-2446
DOCUMENT TYPE: Journal; **General Review**
LANGUAGE: English
AB A review, with 18 refs., on bradykinin analogs which act as kinin antagonists and on structural requirements conferring antagonist activity, tissue specificity, and enzyme resistance.

L11 ANSWER 10 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN
Full Text | Citing References
ACCESSION NUMBER: 1987:44015 HCAPLUS
DOCUMENT NUMBER: 106:44015
TITLE: Bradykinin competitive antagonists: design and applications
AUTHOR(S): Stewart, J. M.; Vavrek, R. J.
CORPORATE SOURCE: Med. Sch., Univ. Colorado, Denver, CO, 80262, USA
SOURCE: Protides of the Biological Fluids (1986), 34, 473-6
CODEN: PBFPA6; ISSN: 0079-7065

DOCUMENT TYPE: Journal; **General Review**
LANGUAGE: English
AB A review, with 11 refs., of structure-activity relations of bradykinin [58-82-2] antagonists.

L11 ANSWER 11 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN
Full Text | Citing References
ACCESSION NUMBER: 1978:484899 HCAPLUS
DOCUMENT NUMBER: 89:84899
TITLE: Modifiers of the response to kinins and their interactions with other systems
AUTHOR(S): Stewart, John M.
CORPORATE SOURCE: Dep. Biochem., Univ. Colorado Sch. Med., Denver, CO, USA
SOURCE: DHEW Publ. (NIH) (U. S.) (1976), Volume Date 1974, NIH-76-791, Chem. Biol. Kallikrein-Kinin Syst. Health Dis., 287-94
CODEN: DHEPDG
DOCUMENT TYPE: Report; **General Review**
LANGUAGE: English
AB A review with 42 refs. on bradykinin [58-82-2] inhibitors and esp. kinin potentiators.

L11 ANSWER 12 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN
Full Text | Citing References
ACCESSION NUMBER: 1974:92782 HCAPLUS
DOCUMENT NUMBER: 80:92782
TITLE: Gel filtration
AUTHOR(S): Moriya, Hiroshi
CORPORATE SOURCE: Fac. Pharm., Sci. Univ. Tokyo, Tokyo, Japan
SOURCE: Seibutsu Butsuri Kagaku (1973), 17(3), 155-61
CODEN: SBBKA4; ISSN: 0031-9082
DOCUMENT TYPE: Journal; **General Review**
LANGUAGE: Japanese
AB Gel filtration is reviewed with 5 examples. They are the purifn. of human pancreatic kallikrein after (NH4)2SO4 fractionation, the estn. of mol. wt. of potato kallikrein inhibitors and bradykinin-inactivating enzyme from potatoes, the application of human serum profile to clin. diagnosis, the change of eluent vol. of buffer in enzymes with and without substrate, and the denaturation of RNase by urea.

```
=> s bradykinin () eczem?
         16404 BRADYKININ
           191 BRADYKININS
         16431 BRADYKININ
                 (BRADYKININ OR BRADYKININS)
          3535 ECZEM?
L12          0 BRADYKININ (W) ECZEM?

=> d his

     (FILE 'HOME' ENTERED AT 23:03:30 ON 09 JUN 2004)

     FILE 'REGISTRY' ENTERED AT 23:03:36 ON 09 JUN 2004

     FILE 'HCAPLUS' ENTERED AT 23:04:24 ON 09 JUN 2004
L1           671 S BRADYKININ () ?AGONIST?
```

```
L2            58 S L1 AND VASCU?
L3             1 S L2 AND DIABET?
L4             0 S L3 AND REVIEW/DT
L5             4 S L2 AND REVIEW/DT
L6             9 S L1 AND DIAB?
L7             1 S L6 AND REVIEW/DT
L8             4 S L1 AND PSORI?
L9             0 S L8 AND REVIEW/DT
L10          319 S BRADYKININ () ?INHIB?
L11           12 S L10 AND REVIEW/DT
L12            0 S BRADYKININ () ECZEM?

=> s l1 and eczem?
          3535 ECZEM?
L13          1 L1 AND ECZEM?

=> s l13 and review/dt
       1732992 REVIEW/DT
L14          0 L13 AND REVIEW/DT

=> s l1 and spasm?
         13409 SPASM?
L15          8 L1 AND SPASM?

=> s l15 and review/dt
       1732992 REVIEW/DT
L16          0 L15 AND REVIEW/DT

=> s l1 and chrohn?
             7 CHROHN?
L17          0 L1 AND CHROHN?

=> s l1 and ulcer?
         32459 ULCER?
L18          3 L1 AND ULCER?

=> s l18 and review/dt
       1732992 REVIEW/DT
L19          0 L18 AND REVIEW/DT

=> s l18 and pancr?
        107327 PANCR?
L20          1 L18 AND PANCR?

=> s l20 and review/dt
       1732992 REVIEW/DT
L21          0 L20 AND REVIEW/DT

=>
```